In human sarcomas, the composition of the immune cell populations and in particular B and T cells, have been demonstrated to better predict response to immune checkpoint inhibitors, compared with the classically accepted biomarkers, such as the tumor mutational burden and the PD-L1 expression [95]. The gene discussed is CD274; the disease is neoplasm.